ArticleCureus2026
Management of Erectile Dysfunction in Middle-Aged Men: A Prospective Evaluation of Lifestyle and Pharmacological Treatments in a Tertiary Care Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Erectile Dysfunction: A Comprehensive Review of Pathophysiology, Diagnosis and Contemporary Management.Medicina (Kaunas, Lithuania) · 2026Review
- Associations Among Obesity, Dietary Habits, and Erectile Dysfunction in Cardiac Patients: A Cross-Sectional Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Erectile dysfunction (ED) is a common condition in middle-aged men and is frequently associated with metabolic and cardiovascular comorbidities. Pharmacological therapy is effective for symptom control, but lifestyle modification may provide additional benefits when used in combination. Objective The objective of this study is to evaluate changes in erectile function and selected metabolic and hormonal parameters following combined lifestyle modification and pharmacological therapy in middle-aged men with erectile dysfunction. Methods This prospective observational study enrolled 60 men aged 40-65 years with erectile dysfunction and at least one metabolic or cardiovascular comorbidity. All participants received daily tadalafil (5 mg), along with structured counselling on diet, physical activity, sleep hygiene, weight management, smoking cessation, and alcohol reduction for three months. Erectile function was assessed using the Sexual Health Inventory for Men (SHIM) questionnaire. Laboratory parameters, including glycated hemoglobin (HbA1c), lipid profile, serum testosterone, and body weight, were measured at baseline and at three months. Paired t-tests were used to compare pre-intervention to post-intervention values, with statistical significance set at p < 0.05. Results The mean SHIM score increased from 14 ± 4 at baseline to 22 ± 5 at three months (mean change: +8 points; 95% CI: 6.2-9.7; p < 0.05). HbA1c decreased from 7.9% ± 1.5% to 6.8% ± 0.8% (-13.9%; p < 0.05), and LDL cholesterol decreased from 200 ± 50 mg/dL to 75 ± 20 mg/dL (-62.5%; p < 0.05). Mean total testosterone levels increased from 270 ± 60 ng/dL to 500 ± 120 ng/dL (+85.2%; p < 0.05), while mean body weight decreased from 85.0 ± 12 kg to 79.0 ± 9 kg (-7.1%; p < 0.05). No serious adverse events were reported. Conclusion In this prospective observational study, combined lifestyle modification and pharmacological management were associated with improvements in erectile function, glycemic control, lipid profile, serum testosterone levels, and body weight among middle-aged men with erectile dysfunction and cardiometabolic comorbidities. Further controlled studies are needed to confirm these findings and assess long-term outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.